Glioblastoma, brain metastases and soft tissue sarcoma of extremities: Candidate tumors for BNCT

• BSH leads to high 10B concentration ratios between sarcoma, muscle and brain as well as between glioblastoma and brain.
• The 10B concentration in tumors is quite low as is the 10B concentration ratio between tumors and blood.
• BPA-f leads to 10B accumulation in tumors relative to blood and advantageous absolute 10B concentrations in tumors.
• The 10B concentration ratios between tumors and brain and sarcoma and muscle, are modest.
• The advantage of the sequential injection of both compounds is an enhanced intratumoral 10B concentration.

10B-concentration ratios between human glioblastoma multiforme (U87MG), sarcoma (S3) and melanoma (MV3) xenografted in nu/nu mice and selected normal tissues were investigated to test for preferential 10B-accumulation. Animals received BSH, BPA or both compounds sequentially. Mean 10B-concentration ratios between tumor and normal tissues above 2 were found indicating therapeutic ratios. In addition to glioblastoma, brain metastases and soft tissue sarcoma appear to be promising targets for future BNCT research.